"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2013/0203769 A1,138-694-892-645-887,2013-08-08,2013,US 201313761765 A,2013-02-07,US 201313761765 A;;US 201261596258 P,2012-02-08,Targeting Metabolic Adaptive Responses to Chemotherapy,"Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC, in association with administration of at least one antagonist of PPARα, PPARδ, or PGC1α. In various embodiments, the compound that inhibits S6K1, mTORC, or upstream or downstream pathway components of S6K1 or mTORC is rapamycin, everolimus, temsirolimus, or imatinib. The antagonist of PPARα, PPARδ, or PGC1α can be GW7647, GW6471, GW501516, GSK3787, or GSK0660.",UNIV CINCINNATI;;UNIV CINCINNATI,PLAS DAVID;;GALLO CATHERINE,UNIVERSITY OF CINCINNATI (2013-02-07),https://lens.org/138-694-892-645-887,Patent Application,yes,3,0,1,4,0,A61K45/06;;A61K45/06;;A61K31/436;;A61K31/436,A61K45/06;;A61K31/436,514/253.03;;514/291;;514/293;;514/562;;514/374;;514/365;;514/347;;514/445,0,0,,,,DISCONTINUED
2,US,A1,US 2016/0193190 A1,121-146-885-740-523,2016-07-07,2016,US 201615019265 A,2016-02-09,US 201615019265 A;;US 201313761765 A;;US 201261596258 P,2012-02-08,Targeting Metabolic Adaptive Responses to Chemotherapy,"Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPARα, PPARδ, or PGC1α. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPARα, PPARδ, or PGC1α can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.",UNIV CINCINNATI,PLAS DAVID;;GALLO CATHERINE,UNIVERSITY OF CINCINNATI (2016-08-15),https://lens.org/121-146-885-740-523,Patent Application,yes,2,1,3,4,0,A61K31/436;;A61K31/436;;A61K31/381;;A61K31/381;;A61K31/421;;A61K31/421;;A61K45/06;;A61K45/06,A61K31/436;;A61K31/381;;A61K31/421,,1,1,039-733-209-425-952,10.1182/blood-2004-06-2494;;15550488,"Recher et al., Blood, 20005;105(6):2527-2534",DISCONTINUED
3,US,A1,US 2013/0338023 A1,137-640-144-752-724,2013-12-19,2013,US 201113878793 A,2011-10-12,EP 10187271 A;;EP 2011067809 W,2010-10-12,BACH2 REPRESSION IN CELLS,"A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.",WILLARD-GALLO KAREN;;SIBILLE CATHERINE;;UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,UNIVERSITE LIBRO DE BRUXELLES (2013-04-23),https://lens.org/137-640-144-752-724,Patent Application,yes,1,3,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,C12Q1/68,506/9;;435/6.11;;435/325;;530/351;;530/317;;530/389.6;;536/18.1,4,4,117-513-554-450-043;;117-440-064-273-668;;075-535-833-102-741;;031-615-040-553-634,15951288;;15996933;;10.1152/ajprenal.00020.2006;;16735461;;21480388;;10.1002/mc.20716;;pmc3080437,"Ravoet et al., ""6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome,"" Haematologica 2005, 90:753-765.;;Chalandon et al., ""Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies"", Haematologica 2005, 90:949-968.;;Baldwin et al., ""Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases,"" Am. J. Physiol. Renal. Physiol. 2006, 291:F960-F971.;;Yadav et al., ""Fyn Is Induced by Ras/PI3K/Akt Signaling and Is Required for Enhanced Invasion/Migration,"" Mol. Carcinog. 2011, 50:346-352.",ACTIVE
4,EP,B1,EP 2627780 B1,023-435-945-334-139,2018-02-21,2018,EP 11770417 A,2011-10-12,EP 10187271 A;;EP 2011067809 W;;EP 11770417 A,2010-10-12,BACH2 REPRESSION IN CELLS,,UNIVERSITÉ LIBRE DE BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/023-435-945-334-139,Granted Patent,yes,0,0,8,8,0,C12N15/113;;C12N2310/14;;C12Q1/6841;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;A61P35/00;;A61P37/08;;C12N15/113;;C12N2310/14;;C12Q1/6841;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C12Q1/68,,2,2,010-628-923-526-235;;019-823-626-986-375,16258099;;10.1200/jco.2005.02.1626;;pmc2733874;;10.1158/1535-7163.mct-05-0155;;16648555,"E. SAKANE-ISHIKAWA ET AL: ""Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group"", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 31, 1 November 2005 (2005-11-01), US, pages 8012 - 8017, XP055330598, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.02.1626;;BUSSEY K J ET AL: ""Integrating data on DNA Copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel"", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 5, no. 4, 1 April 2006 (2006-04-01), pages 853 - 867, XP003017939, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-05-0155",ACTIVE
5,US,B2,US 9828644 B2,021-505-399-315-683,2017-11-28,2017,US 201113878793 A,2011-10-12,EP 10187271 A;;EP 2011067809 W,2010-10-12,BACH2 repression in cells,"A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.",WILLARD-GALLO KAREN;;SIBILLE CATHERINE;;UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,UNIVERSITE LIBRO DE BRUXELLES (2013-04-23),https://lens.org/021-505-399-315-683,Granted Patent,yes,3,0,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;C12N15/113,,20,16,117-513-554-450-043;;117-440-064-273-668;;075-535-833-102-741;;031-615-040-553-634;;146-601-753-657-073;;010-628-923-526-235;;056-464-372-256-072;;044-553-737-378-371;;004-081-832-854-563;;004-245-299-080-130;;006-383-386-276-914;;047-509-318-129-160;;031-593-735-018-748;;056-720-478-240-087;;009-649-116-225-871;;073-146-912-031-02X,15951288;;15996933;;10.1152/ajprenal.00020.2006;;16735461;;21480388;;10.1002/mc.20716;;pmc3080437;;19608752;;10.1182/blood-2008-08-175091;;16258099;;10.1200/jco.2005.02.1626;;7680764;;10.1056/nejm199304083281404;;10.1182/blood-2002-12-3656;;12829606;;11923289;;10.1074/jbc.m112003200;;10.1002/gcc.20390;;17044046;;10.1128/mcb.16.11.6083;;pmc231611;;8887638;;10.1038/sj/leu/2401302;;10.1038/sj.leu.2401302;;10025904;;10.1038/sj.onc.1203716;;10949928;;11746976;;10.1002/gcc.1200;;10.1038/nmeth914;;16929312;;10.1016/0958-1669(92)90078-w;;1368935,"Ravoet et al., “6q—is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome,” Haematologica 2005, 90:753-765.;;Chalandon et al., “Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies”, Haematologica 2005, 90:949-968.;;Baldwin et al., “Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases,” Am. J. Physiol. Renal. Physiol. 2006, 291 :F960-F971.;;Yadav et al., “Fyn Is Induced by Ras/PI3K/Akt Signaling and Is Required for Enhanced Invasion/Migration,” Mol. Carcinog. 2011, 50:346-352.;;Ravoet et al., “Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways”, Blood, vol. 114, No. 14, 2009, pp. 2969-2983.;;Sakane-Ishikawa et al., “Prognostic Significance of BACH2 Expression Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group”, Journal of Clinical Oncology, vol. 23, No. 31, 2005, pp. 8012-8017.;;BROCKHOFF ET AL.: ""Fluorescent mRNA HER2 FISH:"", IMAGING AND MICROSCOPY, 10 August 2010 (2010-08-10), XP009154916;;Fisher et al., “Comparison of a Standard Regimen (CHOP) With Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma”, The New England Journal of Medicine, vol. 328, No. 14, 2003, pp. 1002-1006.;;International Search Report and Written Opinion from International Application No. PCT/EP2011/067809 dated Jan. 5, 2012.;;Kamio et al., “B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs”, Blood, vol. 102, No. 9, 2003, pp. 3317-3322.;;Muto et al., “Activation of Maf/AP-1 Repressor Bach2 by Oxidative Stress Promotes Apoptosis and Its Interaction with Promyelocytic Leukemia Nuclear Bodies”, The Journal of Biological Chemistry, vol. 277, No. 23, 2002, pp. 20724-20733.;;New England BioLabs, “pMal™ Protein Fusion and Purification System”, Version 5.1, 2003, pp. 1-54.;;Ono et al., “Nuclear Positioning of the BACH2 Gene in BCR-ABL Positive Leukemic Cells”, Genes, Chromosomes & Cancer, vol. 46, No. 1, 2007, pp. 67-74.;;Oyake et al., “Bach Proteins Belong to a Novel Family of BTB-Basic Leucine Zipper Transcription Factors that Interact with MafK and Regulate Transcription through the NF-E2 Site”, Molecular and Cellular Biology, vol. 16, No. 11, 1996, pp. 6083-6095.;;Puthier et al. “Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy”, Leukemia, vol. 13, No. 2, 1999, pp. 289-294.;;Sasaki et al., “Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15”, Oncogene, vol. 19, No. 33, 2000, pp. 3739-3749.;;Sibille et al., “Genetic and phenotypic characterization of the lymphocytic variant of the hypereosinophilic syndrome: a model of T lymphomagenesis”, Belgian Journal of Hematology, vol. 1, Issue 2, 2010, pp. 67-70.;;Vieira et al., “Transcription Factor BACH2 Is Transcriptionally Regulated by the BCR/ABL Oncogene”, Genes, Chromosomes & Cancer, vol. 32, No. 4, 2001, pp. 353-363.;;Wiznerowicz et al., “Tuning silence: conditional systems for RNA interference”, Nature Methods, vol. 3, No. 9, 2006, pp. 682-688.;;Yarranton, “Inducible vectors for expression in mammalian cells”, Current Opinion in Biotechnology, vol. 3, No. 5, 1992, pp. 506-511.",ACTIVE
6,WO,A1,WO 2012/049211 A1,179-688-441-133-010,2012-04-19,2012,EP 2011067809 W,2011-10-12,EP 10187271 A,2010-10-12,BACH2 REPRESSION IN CELLS,"A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.",UNIV BRUXELLES;;WILLARD-GALLO KAREN;;SIBILLE CATHERINE,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/179-688-441-133-010,Patent Application,yes,2,0,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,18,15,044-553-737-378-371;;006-383-386-276-914;;009-649-116-225-871;;073-146-912-031-02X;;056-464-372-256-072;;031-593-735-018-748;;004-081-832-854-563;;056-720-478-240-087;;004-245-299-080-130;;047-509-318-129-160;;146-601-753-657-073;;010-628-923-526-235;;146-601-753-657-073;;020-977-124-809-229;;117-513-554-450-043,10.1182/blood-2002-12-3656;;12829606;;10.1128/mcb.16.11.6083;;pmc231611;;8887638;;10.1038/nmeth914;;16929312;;10.1016/0958-1669(92)90078-w;;1368935;;7680764;;10.1056/nejm199304083281404;;10.1038/sj.onc.1203716;;10949928;;11923289;;10.1074/jbc.m112003200;;11746976;;10.1002/gcc.1200;;10.1002/gcc.20390;;17044046;;10.1038/sj/leu/2401302;;10.1038/sj.leu.2401302;;10025904;;19608752;;10.1182/blood-2008-08-175091;;16258099;;10.1200/jco.2005.02.1626;;19608752;;10.1182/blood-2008-08-175091;;10.1016/s0166-0934(00)00289-5;;11226568;;15951288,"KAMIO TAKUYA ET AL: ""B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs."", BLOOD 1 NOV 2003 LNKD- PUBMED:12829606, vol. 102, no. 9, 1 November 2003 (2003-11-01), pages 3317 - 3322, XP002628799, ISSN: 0006-4971;;OYAKE T ET AL: ""Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with Mafk and regulate transcription through the NF-E2 site"", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 16, no. 11, 1 November 1996 (1996-11-01), pages 6083 - 6095, XP002990362, ISSN: 0270-7306;;NEW ENGLAND BIOLABS: ""pMAL TM Protein Fusion and Purification System"", 2003, XP002628800, Retrieved from the Internet <URL:http://130.15.90.245/methods/handbooks%20and%20manuals/NEB%20pMAL%20system.pdf> [retrieved on 20110316];;WIZNEROWICZ MACIEJ ET AL: ""Tuning silence: conditional systems for RNA interference"", NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 3, no. 9, 1 September 2006 (2006-09-01), pages 682 - 688, XP002491627, ISSN: 1548-7091, DOI: DOI:10.1038/NMETH914;;YARRANTON ET AL: ""Inducible vectors for expression in mammalian cells"", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 3, no. 5, 1 October 1992 (1992-10-01), pages 506 - 511, XP023601258, ISSN: 0958-1669, [retrieved on 19921001], DOI: DOI:10.1016/0958-1669(92)90078-W;;FISHER R I ET AL: ""Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma."", THE NEW ENGLAND JOURNAL OF MEDICINE 8 APR 1993 LNKD- PUBMED:7680764, vol. 328, no. 14, 8 April 1993 (1993-04-08), pages 1002 - 1006, XP002628801, ISSN: 0028-4793;;SASAKI S ET AL: ""Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15"", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 19, no. 33, 3 August 2000 (2000-08-03), pages 3739 - 3749, XP002978355, ISSN: 0950-9232, DOI: DOI:10.1038/SJ.ONC.1203716;;MUTO AKIHIKO ET AL: ""Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 7 JUN 2002 LNKD- PUBMED:11923289, vol. 277, no. 23, 7 June 2002 (2002-06-07), pages 20724 - 20733, XP002628802, ISSN: 0021-9258;;SARA A.D. VIEIRA ET AL: ""Transcription factor BACH2 is transcriptionally regulated by theBCR/ABL oncogene"", GENES, CHROMOSOMES AND CANCER, vol. 32, no. 4, 1 December 2001 (2001-12-01), pages 353 - 363, XP055014619, ISSN: 1045-2257, DOI: 10.1002/gcc.1200;;ATSUSHI ONO ET AL: ""Nuclear positioning of theBACH2 gene in BCR-ABL positive leukemic cells"", GENES, CHROMOSOMES AND CANCER, vol. 46, no. 1, 1 January 2007 (2007-01-01), pages 67 - 74, XP055014980, ISSN: 1045-2257, DOI: 10.1002/gcc.20390;;PUTHIER D ET AL: ""Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy"", LEUKEMIA (BASINGSTOKE), vol. 13, no. 2, February 1999 (1999-02-01), pages 289 - 294, XP002666002, ISSN: 0887-6924;;SIBILLE C, WILLARD-GALLO K: ""Genetic and phenotypic characterization of the lymphocytic variant of the hypereosinophilic syndrome: a model of T lymphomagenesis"", BELGIAN JOURNAL OF HEMATOLOGY, vol. 1, no. 2, December 2010 (2010-12-01), pages 67 - 70, XP002666003;;BROCKHOFF ET AL: ""Fluorescent mRNA HER2 FISH:"", 10 August 2010 (2010-08-10), XP009154916, Retrieved from the Internet <URL:http://www.imaging-git.com/science/light-microscopy/fluorescent-mrna- her2-fish>;;RAVOET, M. ET AL., BLOOD., vol. 114, no. 14, 2009, pages 2969 - 2983;;SAKANE-ISHIKAWA ET AL., J. CLIN. ONCOL., vol. 23, 2005, pages 8012 - 8017;;RAVOET M. ET AL., BLOOD, vol. 114, 2009, pages 2969 - 83;;CERVANTES-ACOSTA, G. ET AL., J VIROLOGICAL METHODS, vol. 92, 2001, pages 207 - 213;;RAVOET M. ET AL., HAEMATOLOGICA, vol. 90, 2005, pages 753 - 765",PENDING
7,EP,A1,EP 2627780 A1,198-309-717-077-07X,2013-08-21,2013,EP 11770417 A,2011-10-12,EP 10187271 A;;EP 2011067809 W;;EP 11770417 A,2010-10-12,BACH2 REPRESSION IN CELLS,,UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/198-309-717-077-07X,Patent Application,yes,0,0,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,1,0,,,See references of WO 2012049211A1,ACTIVE
8,DK,T3,DK 2627780 T3,005-408-067-682-538,2018-06-06,2018,DK 11770417 T,2011-10-12,EP 10187271 A;;EP 2011067809 W,2010-10-12,BACH2-REPRESSION I CELLER,,UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/005-408-067-682-538,Granted Patent,no,0,0,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,,,0,0,,,,ACTIVE
9,CA,A1,CA 2814327 A1,032-768-705-236-822,2012-04-19,2012,CA 2814327 A,2011-10-12,EP 10187271 A;;EP 2011067809 W,2010-10-12,BACH2 REPRESSION IN CELLS,"A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.",UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/032-768-705-236-822,Patent Application,no,0,0,8,8,0,A61P35/00;;A61P37/08;;C12Q1/6886;;C12Q1/6886;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,0,0,,,,ACTIVE
10,CA,C,CA 2814327 C,147-989-851-704-419,2019-04-02,2019,CA 2814327 A,2011-10-12,EP 10187271 A;;EP 2011067809 W,2010-10-12,BACH2 REPRESSION IN CELLS,"A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.",UNIV BRUXELLES,WILLARD-GALLO KAREN;;SIBILLE CATHERINE,,https://lens.org/147-989-851-704-419,Granted Patent,no,0,0,8,8,0,C12N15/113;;C12N2310/14;;C12Q1/6841;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;A61P35/00;;A61P37/08;;C12N15/113;;C12N2310/14;;C12Q1/6841;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C12Q1/68;;A61K38/21;;A61K45/00;;A61P35/00;;A61P37/08;;C12N5/10;;C12Q1/6809;;C12Q1/6813;;C12Q1/6841;;C12Q1/6897,,0,0,,,,ACTIVE
11,FR,B1,FR 2612526 B1,180-726-887-303-838,1990-02-02,1990,FR 8703646 A,1987-03-17,FR 8703646 A,1987-03-17,"PROCEDE DE PREPARATION D'UN ADDITIF SURALCANISE RENFERMANT UN DERIVE DU BORE, L'ADDITIF AINSI OBTENUE ET COMPOSITIONS LUBRIFIANTES RENFERMANT LEDIT ADDITIF",,ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/180-726-887-303-838,Granted Patent,no,0,0,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,,0,0,,,,EXPIRED
12,EP,A1,EP 0308445 A1,088-315-604-032-310,1989-03-29,1989,EP 88902504 A,1988-03-16,FR 8703646 A,1987-03-17,"PROCESS FOR THE PREPARATION OF A SUPERALKALINIZED ADDITIVE CONTAINING AN INORGANIC BORON DERIVATIVE, ADDITIVE PRODUCED BY SAID PROCESS AND LUBRICATING COMPOSITIONS CONTAINING SAID ADDITIVE.","Cette invention concerne un procédé de préparation d'un additif suralcanisé à effet anti-usure pour huiles lubrifiantes par carbonation d'un mélange réactionnel composé d'au moins un détergent, d'un dérivé d'un métal alcalin ou alcalinoterreux, d'au moins un promoteur azoté et/ou oxygéné et d'un dérivé du bore, dans une huile diluante et un solvant hydrocarboné.",ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/088-315-604-032-310,Patent Application,yes,0,0,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,,0,0,,,,EXPIRED
13,EP,B1,EP 0308445 B1,103-781-747-938-136,1991-08-28,1991,EP 88902504 A,1988-03-16,FR 8703646 A,1987-03-17,"PROCESS FOR THE PREPARATION OF A SUPERALKALINIZED ADDITIVE CONTAINING AN INORGANIC BORON DERIVATIVE, ADDITIVE PRODUCED BY SAID PROCESS AND LUBRICATING COMPOSITIONS CONTAINING SAID ADDITIVE",,"ELF FRANCE, SOCIETE ANONYME DITE:","HOORNAERT, PIERRE;;REY, CLAUDE;;GALLO, ROGER;;BELLE, CATHERINE",,https://lens.org/103-781-747-938-136,Granted Patent,yes,7,0,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,,0,0,,,,EXPIRED
14,WO,A1,WO 1988/007073 A1,009-163-303-934-526,1988-09-22,1988,FR 8800137 W,1988-03-16,FR 8703646 A,1987-03-17,"PROCESS FOR THE PREPARATION OF A SUPERALKANIZED ADDITIVE CONTAINING A BORON DERIVATIVE, ADDITIVE PRODUCED BY SAID PROCESS AND LUBRICATING COMPOSITIONS CONTAINING SAID ADDITIVE","Process for the preparation of a superalkanized additive with an anti-wear effect for lubricating oils, said process consisting of the carbonation of a reactive mixture composed of at least one detergent, of a derivate of an alkaline or alkaline-earth metal, at least one azotized and/or oxygenized promoter and a boron derivate, in a diluent oil and a hydrocarbon solvent.",ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/009-163-303-934-526,Patent Application,yes,7,6,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,C4X X13           X13,0,0,,,,PATENTED
15,FR,A1,FR 2612526 A1,098-803-338-307-478,1988-09-23,1988,FR 8703646 A,1987-03-17,FR 8703646 A,1987-03-17,"PROCEDE DE PREPARATION D'UN ADDITIF SURALCANISE RENFERMANT UN DERIVE DU BORE, L'ADDITIF AINSI OBTENUE ET COMPOSITIONS LUBRIFIANTES RENFERMANT LEDIT ADDITIF","<P>CETTE INVENTION CONCERNE UN PROCEDE DE PREPARATION D'UN ADDITIF SURALCALINISE A EFFET ANTIUSURE POUR HUILES LUBRIFIANTES PAR CARBONATATION D'UN MELANGE REACTIONNEL COMPOSE D'AU MOINS UN DETERGENT, D'UN DERIVE D'UN METAL ALCALIN OU ALCALINOTERREUX, D'AU MOINS UN PROMOTEUR AZOTE ETOU OXYGENE ET D'UN DERIVE DU BORE, DANS UNE HUILE DILUANTE ET UN SOLVANT HYDROCARBONE.</P>",ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/098-803-338-307-478,Patent Application,no,5,0,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,,0,0,,,,EXPIRED
16,US,A,US 5098587 A,127-873-030-015-448,1992-03-24,1992,US 54667090 A,1990-06-29,FR 8703646 A,1987-03-17,"PROCESS FOR THE PREPARATION OF AN OVERALKALINIZED ADDITIVE CONTAINING A DERIVATIVE OF BORON, THE ADDITIVE THUS OBTAINED AND LUBRICANT COMPOSITIONS CONTAINING SAID ADDITIVE","A process is provided for the preparation of an overalkalinized additive for lubricant oils which consists of carbonating a reaction mixture composed of at least one detergent, one derivative of alkaline or alkaline earth metal, at least one nitrogenized and/or oxygenated promoter in a diluent oil and a hydrocarbonated solvent, and wherein the operation is carried out in the presence of at least one boron derivative. Also provided, the additives thus obtained and lubricant compositions containing the additive. These additives are homogeneous and stable, and have very good antiwear properties.",ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/127-873-030-015-448,Granted Patent,yes,14,8,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,252/33.4;;252/18;;252/40.5;;252/40.7;;252/42;;252/42.1,0,0,,,,EXPIRED
17,DE,D1,DE 3864483 D1,023-534-764-547-921,1991-10-02,1991,DE 3864483 T,1988-03-16,FR 8800137 W;;FR 8703646 A,1987-03-17,"VERFAHREN ZUR HERSTELLUNG EINES EIN ANORGANISCHES BORDERIVAT ENTHALTENDEN UEBERBASISCHEN ADDITIVS, DANACH ERHALTENE ADDITIVE UND DIESE ENTHALTENDE SCHMIERMITTEL.",,ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE,,https://lens.org/023-534-764-547-921,Granted Patent,no,0,0,8,11,0,C10M159/20;;C10M159/22;;C10M159/24;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089;;C10M159/20;;C10M2215/28;;C10M159/22;;C10M2207/26;;C10M159/24;;C10M2207/262;;C10M2219/046;;C10M2219/089;;C10M2207/028,C10M141/06;;C10M141/12;;C10M159/20;;C10M159/22;;C10M159/24;;C10N10/02;;C10N10/04;;C10N30/04;;C10N30/06;;C10N70/00,,0,0,,,,EXPIRED
18,WO,A1,WO 2011/003833 A1,186-669-333-828-886,2011-01-13,2011,EP 2010059482 W,2010-07-02,EP 09164947 A,2009-07-08,DIAGNOSTIC METHOD AND KIT FOR THE DETECTION OF A LYMPHOCYTIC VARIANT OF HYPEREOSINOPHILIC SYNDROME,"The present invention is related to a gene set, a kit and a method for diagnosis of lymphocytic variant hypereosinophilic syndrome.",UNIV BRUXELLES;;UNIV CATHOLIQUE LOUVAIN;;WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE,WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE,,https://lens.org/186-669-333-828-886,Patent Application,yes,2,2,4,4,0,C12Q1/6883;;C12Q2600/158;;C12Q2600/106;;C12Q2600/178;;C12Q1/6883;;C12Q2600/158;;C12Q2600/178;;C12Q2600/106,C12Q1/68,,18,17,008-041-190-000-070;;008-241-338-647-521;;146-737-151-883-914;;146-601-753-657-073;;030-824-106-701-041;;099-585-232-237-073;;073-648-574-197-560;;038-638-460-092-359;;116-196-279-671-112;;117-513-554-450-043;;096-399-370-404-767;;003-925-044-364-572;;004-683-762-528-751;;146-737-151-883-914;;034-651-243-957-820;;031-266-430-105-199;;033-997-194-168-332,10.1200/jco.2007.11.8604;;17785705;;19524963;;10.1016/j.juro.2009.04.023;;10.1016/j.exphem.2005.06.027;;16219537;;19608752;;10.1182/blood-2008-08-175091;;16022566;;10.1517/13543784.14.7.769;;18836589;;10.1358/dnp.2008.21.6.1246831;;pmc1810525;;10.1186/1465-9921-8-16;;17328802;;16750989;;10.1016/j.jaci.2006.02.042;;17920324;;10.1016/j.jbspin.2007.05.004;;15951288;;10419891;;10.1182/blood.v94.3.994.415k26_994_1002;;10.1006/jmbi.2001.5350;;11902839;;16574698;;10.1093/bioinformatics/btl108;;10.1016/j.exphem.2005.06.027;;16219537;;11298328;;10.1002/1521-4141(200104)31:4<1037::aid-immu1037>3.0.co;2-;;10.1002/1521-4141(200104)31:4<1037::aid-immu1037>3.0.co;2-#;;10.1016/j.humimm.2006.02.005;;16690409;;pmc1851905;;15313894;;10.1158/0008-5472.can-04-1253,"ALLAN LIPTON ET AL: ""Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases"", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 28, 1 October 2007 (2007-10-01), pages 4431 - 4437, XP007910792, ISSN: 0732-183X;;FIZAZI K ET AL: ""Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial"", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 182, no. 2, 3 June 2009 (2009-06-03), pages 509 - 516, XP026284163, ISSN: 0022-5347, [retrieved on 20090613];;WILLARD-GALLO ET AL: ""Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome"", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 33, no. 10, 1 October 2005 (2005-10-01), pages 1147 - 1159, XP005108370, ISSN: 0301-472X;;RAVOET M ET AL: ""Molecular profiling of CD3<->CD4<+> T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways"", BLOOD 2009 AMERICAN SOCIETY OF HEMATOLOGY USA, vol. 114, no. 14, 2009, pages 2969 - 2983, XP002562285, ISSN: 0006-4971 1528-0020;;LY T W ET AL: ""Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: An overview"", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200507 GB LNKD- DOI:10.1517/13543784.14.7.769, vol. 14, no. 7, July 2005 (2005-07-01), pages 769 - 773, XP002601687, ISSN: 1354-3784;;PETTIPHER ROY ET AL: ""Antagonists of the prostaglandin D2 receptor CRTH2"", DRUG NEWS AND PERSPECTIVES, PROUS SCIENCE LNKD- DOI:10.1358/DNP.2008.21.6.1246831, vol. 21, no. 6, 1 July 2008 (2008-07-01), pages 317 - 322, XP001537082, ISSN: 0214-0934;;ULLER LENA ET AL: ""Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation"", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB LNKD- DOI:10.1186/1465-9921-8-16, vol. 8, no. 1, 28 February 2007 (2007-02-28), pages 16, XP021021498, ISSN: 1465-9921;;KLION ET AL: ""Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report"", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US LNKD- DOI:10.1016/J.JACI.2006.02.042, vol. 117, no. 6, 1 June 2006 (2006-06-01), pages 1292 - 1302, XP005513523, ISSN: 0091-6749;;FOUQUE-AUBERT ET AL: ""Influence of RANKL inhibition on immune system in the treatment of bone diseases"", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 75, no. 1, 1 January 2008 (2008-01-01), pages 5 - 10, XP022413746, ISSN: 1297-319X;;RAVOET M ET AL., HAEMATOLOGICA, 2005;;RAVOET M ET AL., HAEMATOLOGICA, vol. 90, 2005, pages 753 - 765;;ROUFOSSE F ET AL., BLOOD, vol. 94, 1999, pages 994 - 1002;;ZHANG L ET AL., J MOLBIOL., vol. 317, 2002, pages 225 - 235;;KENNEDY RE ET AL., BIOINFORMATICS, vol. 22, 2006, pages 1272 - 1274;;WILLARD-GALLO KE ET AL., EXPHEMATOL., vol. 33, 2005, pages 1147 - 1159;;DE LAVAREILLE A ET AL., EURJ IMMUNOL., vol. 31, 2001, pages 1037 - 1046;;FREISHTAT RJ ET AL., HUMIMMUNOL., vol. 66, 2005, pages 1223 - 1234;;VAN DOORN R ET AL., CANCER RES., vol. 64, 2004, pages 5578 - 5586",PENDING
19,EP,A1,EP 2451971 A1,131-177-743-278-892,2012-05-16,2012,EP 10732685 A,2010-07-02,EP 2010059482 W;;EP 09164947 A;;EP 10732685 A,2009-07-08,DIAGNOSTIC METHOD AND KIT FOR THE DETECTION OF A LYMPHOCYTIC VARIANT OF HYPEREOSINOPHILIC SYNDROME,,UNIV BRUXELLES;;UNIV CATHOLIQUE LOUVAIN,WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE,,https://lens.org/131-177-743-278-892,Patent Application,yes,0,0,4,4,0,C12Q1/6883;;C12Q2600/158;;C12Q2600/106;;C12Q2600/178;;C12Q1/6883;;C12Q2600/158;;C12Q2600/178;;C12Q2600/106,C12Q1/68,,0,0,,,,DISCONTINUED
20,EP,A1,EP 2272977 A1,154-446-236-668-658,2011-01-12,2011,EP 09164947 A,2009-07-08,EP 09164947 A,2009-07-08,Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome,"The present invention is related to a gene set, a kit and a method for diagnosis of lymphocytic variant hypereosinophilic syndrome.
 
 
",UNIV BRUXELLES;;UNIV CATHOLIQUE LOUVAIN,WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE,,https://lens.org/154-446-236-668-658,Patent Application,yes,1,4,4,4,0,C12Q1/6883;;C12Q2600/158;;C12Q2600/106;;C12Q2600/178;;C12Q1/6883;;C12Q2600/158;;C12Q2600/178;;C12Q2600/106,C12Q1/68,,14,13,008-041-190-000-070;;008-241-338-647-521;;146-737-151-883-914;;146-601-753-657-073;;116-196-279-671-112;;117-513-554-450-043;;096-399-370-404-767;;003-925-044-364-572;;004-683-762-528-751;;146-737-151-883-914;;034-651-243-957-820;;031-266-430-105-199;;033-997-194-168-332,10.1200/jco.2007.11.8604;;17785705;;19524963;;10.1016/j.juro.2009.04.023;;10.1016/j.exphem.2005.06.027;;16219537;;19608752;;10.1182/blood-2008-08-175091;;17920324;;10.1016/j.jbspin.2007.05.004;;15951288;;10419891;;10.1182/blood.v94.3.994.415k26_994_1002;;10.1006/jmbi.2001.5350;;11902839;;16574698;;10.1093/bioinformatics/btl108;;10.1016/j.exphem.2005.06.027;;16219537;;11298328;;10.1002/1521-4141(200104)31:4<1037::aid-immu1037>3.0.co;2-;;10.1002/1521-4141(200104)31:4<1037::aid-immu1037>3.0.co;2-#;;10.1016/j.humimm.2006.02.005;;16690409;;pmc1851905;;15313894;;10.1158/0008-5472.can-04-1253,"ALLAN LIPTON ET AL: ""Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases"", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 28, 1 October 2007 (2007-10-01), pages 4431 - 4437, XP007910792, ISSN: 0732-183X;;FIZAZI K ET AL: ""Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial"", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 182, no. 2, 3 June 2009 (2009-06-03), pages 509 - 516, XP026284163, ISSN: 0022-5347, [retrieved on 20090613];;WILLARD-GALLO ET AL: ""Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome"", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 33, no. 10, 1 October 2005 (2005-10-01), pages 1147 - 1159, XP005108370, ISSN: 0301-472X;;RAVOET M ET AL: ""Molecular profiling of CD3<->CD4<+> T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways"", BLOOD 2009 AMERICAN SOCIETY OF HEMATOLOGY USA, vol. 114, no. 14, 2009, pages 2969 - 2983, XP002562285, ISSN: 0006-4971 1528-0020;;FOUQUE-AUBERT ET AL: ""Influence of RANKL inhibition on immune system in the treatment of bone diseases"", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 75, no. 1, 1 January 2008 (2008-01-01), pages 5 - 10, XP022413746, ISSN: 1297-319X;;RAVOET M ET AL., HAEMATOLOGICA, 2005;;RAVOET M ET AL., HAEMATOLOGICA., vol. 90, 2005, pages 753 - 765;;ROUFOSSE F ET AL., BLOOD., vol. 94, 1999, pages 994 - 1002;;ZHANG L ET AL., J MOLBIOL., vol. 317, 2002, pages 225 - 235;;KENNEDY RE ET AL., BIOINFORMATICS., vol. 22, 2006, pages 1272 - 1274;;WILLARD-GALLO KE ET AL., EXPHEMATOL., vol. 33, 2005, pages 1147 - 1159;;DE LAVAREILLE A ET AL., EURJ IMMUNOL., vol. 31, 2001, pages 1037 - 1046;;FREISHTAT RJ ET AL., HUMIMMUNOL., vol. 66, 2005, pages 1223 - 1234;;VAN DOORN R ET AL., CANCER RES., vol. 64, 2004, pages 5578 - 5586",DISCONTINUED
21,US,A1,US 2012/0289418 A1,014-288-389-186-29X,2012-11-15,2012,US 201013378983 A,2010-07-02,EP 09164947 A;;EP 2010059482 W,2009-07-08,DIAGNOSTIC METHOD AND KIT FOR THE DETECTION OF A LYMPHOCYTIC VARIANT OF HYPEREOSINOPHILIC SYNDROME,"The present invention is related to a gene set, a kit and a method for diagnosis of lymphocytic variant hypereosinophilic syndrome.",WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE;;UNIV CATHOLIQUE LOUVAIN,WILLARD-GALLO KAREN;;RAVOET MARIE;;ROUFOSSE FLORENCE;;SIBILLE CATHERINE,UNIVERSITE LIBRE DE BRUXELLES (2011-12-09);;UNIVERSITE CATHOLIQUE DE LOUVAIN (2011-12-09),https://lens.org/014-288-389-186-29X,Patent Application,yes,0,15,4,4,0,C12Q1/6883;;C12Q2600/158;;C12Q2600/106;;C12Q2600/178;;C12Q1/6883;;C12Q2600/158;;C12Q2600/178;;C12Q2600/106,C07K16/18;;C40B30/04;;C07K16/28;;G01N21/64;;G01N33/566,506/9;;435/6.12;;530/388.15;;436/501;;530/389.8,0,0,,,,DISCONTINUED
22,FR,A1,FR 2755009 A1,022-142-017-112-650,1998-04-30,1998,FR 9612967 A,1996-10-24,FR 9612967 A,1996-10-24,Film-forming aqueous composition for nail varnish with good shine,"Film-forming aqueous composition for nail varnish (I) comprises, as film-forming agent, a copolymer (II) of ethylenically unsaturated monomers (III) dispersed as an aqueous emulsion. At least one of (III) is a (meth)acrylic monomer with a sulphonamide group (IV). Preferably (IV) is an ester of (meth)acrylic acid of formula CH2=C(R)C(O)O-(CH2)m-N(R1)-SO2-R2 (V). (II) is a copolymer of (V), a (meth)acrylic monomer without a sulphonamide group and/or a vinylaromatic monomer. (I) also comprises additives and pigment.",BERGERAC NC,CHIVA VALERIE;;COUTOU MARYSE;;GALLO ROGER;;JEHANNO CATHERINE;;LAFOREST FRANCK,,https://lens.org/022-142-017-112-650,Patent Application,no,9,3,2,2,0,A61Q3/02;;A61K8/8158,A61K8/81;;A61Q3/02,,0,0,,,,EXPIRED
23,FR,B1,FR 2755009 B1,164-849-084-666-31X,1998-11-27,1998,FR 9612967 A,1996-10-24,FR 9612967 A,1996-10-24,VERNIS A ONGLES AQUEUX,,BERGERAC NC,CHIVA VALERIE;;COUTOU MARYSE;;GALLO ROGER;;JEHANNO CATHERINE;;LAFOREST FRANCK,,https://lens.org/164-849-084-666-31X,Granted Patent,no,0,0,2,2,0,A61Q3/02;;A61K8/8158,A61K8/81;;A61Q3/02,,0,0,,,,EXPIRED
24,EP,A2,EP 0383359 A2,050-400-530-994-468,1990-08-22,1990,EP 90104404 A,1988-03-16,EP 90104404 A;;FR 8703646 A,1987-03-17,"Process for preparing an overbased additive containing a boron derivative, additive produced by said process and lubricating compositions containing said additive.","Procédé de préparation d'un additif suralcalinisé renfermant du bore inorganique, par carbonatation d'un mélange réactionnel composé d'un détergent, d'un métal alcalin ou alcalinoterreux et de promoteurs azotés et oxygénés dans une huile diluante et un solvant hydrocarboné. Le dérivé inorganique du bore est introduit dans le mélange réactionnel avant la réaction de carbonatation. L'additif au bore est utilisé comme additif à effet antiusure dans les lubrifiants.  ",ELF FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE CHEZ MME ESCER,ELF ANTAR FRANCE (1993-02-10),https://lens.org/050-400-530-994-468,Patent Application,yes,0,1,3,11,0,C10M159/24;;C10M133/56;;C10M159/20;;C10M159/22;;C10M163/00;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089,C10M159/20;;C10M159/22;;C10M159/24;;C10M163/00,,0,0,,,,EXPIRED
25,EP,B1,EP 0383359 B1,192-915-896-134-835,1993-11-03,1993,EP 90104404 A,1988-03-16,EP 90104404 A;;FR 8703646 A,1987-03-17,"Process for preparing an overbased additive containing a boron derivative, additive produced by said process and lubricating compositions containing said additive.",,ELF ANTAR FRANCE,HOORNAERT PIERRE;;REY CLAUDE;;GALLO ROGER;;BELLE CATHERINE CHEZ MME ESCER,ELF ANTAR FRANCE (1993-02-10),https://lens.org/192-915-896-134-835,Granted Patent,no,0,0,3,11,0,C10M159/24;;C10M133/56;;C10M159/20;;C10M159/22;;C10M163/00;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089,C10M159/20;;C10M159/22;;C10M159/24;;C10M163/00,,0,0,,,,EXPIRED
26,EP,A3,EP 0383359 A3,191-985-498-942-316,1990-11-07,1990,EP 90104404 A,1988-03-16,EP 90104404 A;;FR 8703646 A,1987-03-17,"PROCESS FOR PREPARING AN OVERBASED ADDITIVE CONTAINING A BORON DERIVATIVE, ADDITIVE PRODUCED BY SAID PROCESS AND LUBRICATING COMPOSITIONS CONTAINING SAID ADDITIVE","Procédé de préparation d'un additif suralcalinisé renfermant du bore inorganique, par carbonatation d'un mélange réactionnel composé d'un détergent, d'un métal alcalin ou alcalinoterreux et de promoteurs azotés et oxygénés dans une huile diluante et un solvant hydrocarboné. Le dérivé inorganique du bore est introduit dans le mélange réactionnel avant la réaction de carbonatation. L'additif au bore est utilisé comme additif à effet antiusure dans les lubrifiants.  ",ELF FRANCE,"HOORNAERT, PIERRE;;REY, CLAUDE;;GALLO, ROGER;;BELLE, CATHERINE CHEZ MME ESCERGUEL",ELF ANTAR FRANCE (1993-02-10),https://lens.org/191-985-498-942-316,Search Report,yes,2,0,3,11,0,C10M159/24;;C10M133/56;;C10M159/20;;C10M159/22;;C10M163/00;;C10M2207/028;;C10M2207/26;;C10M2207/262;;C10M2215/28;;C10M2219/046;;C10M2219/089,C10M159/20;;C10M159/22;;C10M159/24;;C10M163/00,,0,0,,,,EXPIRED
27,FR,A1,FR 2822879 A1,100-726-854-223-821,2002-10-04,2002,FR 0104144 A,2001-03-28,FR 0104144 A,2001-03-28,Door glazing slide guide for motor vehicle has coil to generate magnetic field perpendicular to path of movement of glazing,"The door glazing (2) slide guide for a motor vehicle has a coil (8) to generate a magnetic field perpendicular to the path (T) of movement of the glazing. Electrical wires (10) are placed in parallel between two electrical conductors (11,12) continuously fed with current. The electrical wires are perpendicular to the plane defined by the movement path and magnetic field.",MERITOR LIGHT VEHICLE SYS LTD,BREYNAERT FRANCOIS;;LAURANDEL HERVE;;BAUDET MATHILDE;;VIAL JEAN CHARLES;;MASSON CATHERINE;;LE GALLO YANN;;DUFOUR FABIEN;;DOBSON SIMON;;HURT PATRICK,,https://lens.org/100-726-854-223-821,Patent Application,no,3,2,1,1,0,E05F15/60;;E05F15/689;;E05Y2900/55;;H02K7/14;;H02K3/26;;H02K41/0356,E05F15/16;;E05F15/60;;H02K3/26;;H02K7/14;;H02K41/035,,0,0,,,,PENDING
28,FR,A1,FR 2819848 A1,196-261-380-298-949,2002-07-26,2002,FR 0100916 A,2001-01-24,FR 0100916 A,2001-01-24,Cable actuator for motor vehicle has electric motor and rack cable with external thread engaged by drive worm on motor,The cable actuator has an electric motor (12) and a rack cable (6) which is flexible and slides inside a sheath (7). The cable has a peripheral thread (8) which is engaged by a worm (10) driven by the motor. The motor shaft (11) can be mounted in a housing (14) fixed to the motor and having cable guides.,MERITOR LIGHT VEHICLE SYS LTD,BAUDET MATHILDE;;BREYNAERT FRANCOIS;;DOBSON SIMON;;DUFOUR FABIEN;;HURT PATRICK;;LAURANDEL HERVE;;LE GALLO YANN;;VIAL JEAN CHARLES;;MASSON CATHERINE,,https://lens.org/196-261-380-298-949,Patent Application,no,3,3,2,2,0,E05F11/426;;E05F15/689;;E05F15/697;;E05Y2900/55;;F16H19/06;;F16H19/0645,E05F11/42;;E05F15/16;;F16H19/00,,0,0,,,,EXPIRED
29,FR,B1,FR 2819848 B1,037-642-415-692-81X,2007-06-08,2007,FR 0100916 A,2001-01-24,FR 0100916 A,2001-01-24,DISPOSITIF DE MANOEUVRE PAR CABLE D'UN OUVRANT DE VEHICULE,,MERITOR LIGHT VEHICLE SYS LTD,BAUDET MATHILDE;;BREYNAERT FRANCOIS;;DOBSON SIMON;;DUFOUR FABIEN;;HURT PATRICK;;LAURANDEL HERVE;;LE GALLO YANN;;VIAL JEAN CHARLES;;MASSON CATHERINE,,https://lens.org/037-642-415-692-81X,Granted Patent,no,0,0,2,2,0,E05F11/426;;E05F15/689;;E05F15/697;;E05Y2900/55;;F16H19/06;;F16H19/0645,E05F15/10;;B60J1/17;;B60J7/02;;B60J7/057;;E05F11/42;;E05F15/16;;F16H19/00,,0,0,,,,EXPIRED
30,AU,A1,AU 2022/284952 A1,168-616-076-268-395,2023-12-14,2023,AU 2022/284952 A,2022-06-03,US 202163196933 P;;US 202163196937 P;;US 202163285197 P;;US 202163285201 P;;US 2022/0032253 W,2021-06-04,"SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE","Provided is a solid dispersion of (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (Compound 1), defined as described herein, or a pharmaceutically acceptable salt thereof and a tablet containing the solid dispersion for treating pain. Also disclosed herein is Compound 1 or a pharmaceutically acceptable salt thereof for use in a method of treating pain.",VERTEX PHARMA,KARKARE RADHIKA;;CHU CATHY;;CIRINCIONE BRENDA;;CORRELL DARIN J;;DELFF PHILIP KAJ HARDER;;DINEHART KIRK RAYMOND;;BENITO GALLO PALOMA;;HAY TANYA LOUISE;;JIANG LICONG;;JONES JAMES B;;MCCARTY KATIE L;;METZLER CATHERINE P;;MILLER JONATHAN M;;PETERSON MARK C;;ROOPWANI RAHUL;;STAROPOLI JOHN F,,https://lens.org/168-616-076-268-395,Patent Application,no,0,0,5,5,0,A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00;;A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00,A61K31/443;;A61K9/20;;A61P23/00;;A61P25/02;;A61P29/00,,0,0,,,,PENDING
31,IL,A,IL 308954 A,016-268-094-805-879,2024-01-01,2024,IL 30895423 A,2023-11-29,US 202163196933 P;;US 202163196937 P;;US 202163285197 P;;US 202163285201 P;;US 2022/0032253 W,2021-06-04,"Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide",,VERTEX PHARMA;;KARKARE RADHIKA;;CHU CATHY;;CIRINCIONE BRENDA;;CORRELL DARIN J;;DELFF PHILIP KAJ HARDER;;DINEHART KIRK RAYMOND;;BENITO GALLO PALOMA;;HAY TANYA LOUISE;;JIANG LICONG;;JONES JAMES B;;MCCARTY KATIE L;;METZLER CATHERINE P;;MILLER JONATHAN M;;PETERSON MARK C;;ROOPWANI RAHUL;;STAROPOLI JOHN F,KARKARE RADHIKA;;CHU CATHY;;CIRINCIONE BRENDA;;CORRELL DARIN J;;DELFF PHILIP KAJ HARDER;;DINEHART KIRK RAYMOND;;BENITO GALLO PALOMA;;HAY TANYA LOUISE;;JIANG LICONG;;JONES JAMES B;;MCCARTY KATIE L;;METZLER CATHERINE P;;MILLER JONATHAN M;;PETERSON MARK C;;ROOPWANI RAHUL;;STAROPOLI JOHN F,,https://lens.org/016-268-094-805-879,Patent Application,no,0,0,5,5,0,A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00;;A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00,A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00,,0,0,,,,PENDING
32,CA,A1,CA 3222197 A1,092-277-389-821-64X,2022-12-08,2022,CA 3222197 A,2022-06-03,US 202163196933 P;;US 202163196937 P;;US 202163285197 P;;US 202163285201 P;;US 2022/0032253 W,2021-06-04,"SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE","Provided is a solid dispersion of (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (Compound 1), defined as described herein, or a pharmaceutically acceptable salt thereof and a tablet containing the solid dispersion for treating pain. Also disclosed herein is Compound 1 or a pharmaceutically acceptable salt thereof for use in a method of treating pain.",VERTEX PHARMA,KARKARE RADHIKA;;DELFF PHILIP KAJ HARDER;;DINEHART KIRK RAYMOND;;PETERSON MARK C;;ROOPWANI RAHUL;;STAROPOLI JOHN F;;HAY TANYA LOUISE;;JIANG LICONG;;JONES JAMES B;;CHU CATHY;;METZLER CATHERINE P;;BENITO GALLO PALOMA;;CIRINCIONE BRENDA;;CORRELL DARIN J;;MCCARTY KATIE L;;MILLER JONATHAN M,,https://lens.org/092-277-389-821-64X,Patent Application,no,0,0,5,5,0,A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00;;A61K9/2054;;A61K9/2013;;A61K31/443;;A61P23/00;;A61P25/02;;A61P29/00,A61K31/443;;A61K9/20;;A61P23/00;;A61P25/02;;A61P29/00,,0,0,,,,PENDING
